$BMY (Bristol-Myers Squibb Company)

$BMY {{ '2016-08-03T20:34:21+0000' | timeago}} • Announcement

The BoD of $BMY declared a quarterly dividend of $0.50 per share on the $2.00 convertible preferred stock of the corporation, payable December 1, 2016, to stockholders of record on November 8, 2016.

$ACET {{ '2018-01-02T20:11:33+0000' | timeago}} • Announcement

$ACET's finished dosage form generics subsidiary Rising Pharmaceuticals launched the first generic for Efavirenz Capsules. This is an FDA-approved generic version of the reference listed drug, Sustiva from $BMY, which in combination with other drugs is indicated for the treatment of HIV-1 infection in adults and pediatric patients.

$BMY {{ '2017-12-18T12:54:53+0000' | timeago}} • Announcement

$BMY announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency recommended the approval of Yervoy for pediatric patients 12 years of age and older who have unresectable or metastatic melanoma. The CHMP recommendation will now be reviewed by the European Commission.

$SGEN {{ '2017-12-11T16:30:10+0000' | timeago}} • Announcement

$SGEN and $BMY highlighted updated interim results from an ongoing phase 1/2 clinical trial evaluating the combination of Adcetris (brentuximab vedotin) and Opdivo (nivolumab) in relapsed or refractory classical Hodgkin lymphoma (HL).

$BMY {{ '2017-12-07T23:37:10+0000' | timeago}} • Announcement

$BMY declared a 2.6% hike in the quarterly dividend, beginning in 1Q18. The increase will result in a quarterly dividend of $0.40 per share. The next quarterly dividend will be payable on Feb. 1, 2018, to stockholders of record at the close of business on Jan. 5, 2018.

$BMY {{ '2017-12-07T18:05:15+0000' | timeago}} • Announcement

$BMY announced the FDA lifted partial clinical holds placed on CA209 -039 and CA204142, the phase 1 and 2 clinical trials investigating Opdivo (nivolumab)-based combinations in patients with relapsed or refractory multiple myeloma, respectively.

$BMY {{ '2017-12-01T13:38:19+0000' | timeago}} • Announcement

$BMY announced that the Phase 3 study of Opdivo (nivolumab) versus docetaxel was stopped early because the independent Data Monitoring Committee (DMC) concluded that the study met its primary endpoint, demonstrating superior overall survival in patients receiving Opdivo compared with the control arm.

$LH {{ '2017-11-15T14:38:42+0000' | timeago}} • Announcement

$LH announced the U.S. availability of the PD-L1 IHC 28-8 pharmDx assay as a complementary diagnostic for two newly approved indications. This is in connection with the use of $BMY's Opdivo (nivolumab) to treat patients with metastatic urothelial carcinoma, also referred to as bladder cancer, and squamous cell carcinoma of the head and neck.

$BMY {{ '2017-10-26T23:35:43+0000' | timeago}} • Webcast

Looking ahead, $BMY expects to see the final results for the combination in first-line non-small cell lung cancer from CheckMate-227 in the first half of FY18.

$BMY {{ '2017-10-26T23:34:56+0000' | timeago}} • Webcast

Regarding the developing situation in Puerto Rico, $BMY does not expect to have any supply disruption, the company said as it posted 3Q17 results.

$BMY {{ '2017-10-26T23:30:45+0000' | timeago}} • Infographic

$BMY Bristol-Myers Squibb Co Earnings AlphaGraphic: Q3 2017 highlights

$BMY {{ '2017-10-26T13:52:34+0000' | timeago}} • Announcement

As the big pharma posted 3Q17 results, $BMY announced that it now sees FY17 GAAP EPS guidance in the range $2.36-2.46 and non-GAAP EPS at about $2.95-3.05.

$BMY {{ '2017-10-26T13:49:37+0000' | timeago}} • Announcement

With strong sales for key products Opdivo and Eliquis and multiple regulatory approvals for Opdivo, $BMY saw 3Q17 revenues jump 7% to $5.3Bil. The pharma giant saw diluted EPS slip 29% to $0.51 with net attributable earnings of $845MM.

$BMY {{ '2017-09-25T13:27:21+0000' | timeago}} • Announcement

$BMY's Opdivo (nivolumab) receives FDA approval for intravenous use for the treatment of hepatocellular carcinoma patients previously treated with Sorafenib.

$ABBV {{ '2017-09-22T11:48:04+0000' | timeago}} • Announcement

$ABBV and $BMY announced a clinical trial collaboration to evaluate the combination of AbbVie's investigational antibody drug conjugate ABBV-399 and Bristol-Myers Squibb's immunotherapy Opdivo (nivolumab) in c-Met overexpressing non-small cell lung cancer (NSCLC).

$BMY {{ '2017-09-22T11:37:45+0000' | timeago}} • Announcement

$BMY announced that Japan Ministry of Health, Labor and Welfare approved 'Opdivo.' The nivolumab drug is used in the treatment of patients with unresectable advanced or recurrent gastric cancer progressing after chemotherapy.

$BMY {{ '2017-09-13T20:46:25+0000' | timeago}} • Announcement

$BMY declared a quarterly dividend of $0.39 per share on the $.10 par value common stock of the corporation. The next quarterly dividend will be payable on November 1, 2017, to stockholders of record at the close of business on October 6, 2017.

$BMY {{ '2017-09-13T20:29:36+0000' | timeago}} • Announcement

$BMY elected Karen Vousden, effective Jan 1, 2018. to serve as a member of the Science and Technology Committee of the Board of Directors. Dr. Vousden is currently group leader at the Francis Crick Institute in London and the Chief Scientist at Cancer Research UK.

$BMY {{ '2017-09-11T10:59:32+0000' | timeago}} • Announcement

$BMY said Opdivo plus Yervoy combination demonstrated superior overall survival and showed durable responses in patients with previously untreated advanced or metastatic renal cell carcinoma in phase 3 CheckMate -214 trial. The combination lowered the risk of death by 37% and improved overall survival in all randomized patients.

$BMY {{ '2017-09-07T13:34:21+0000' | timeago}} • Announcement

$BMY said a Phase 3 study evaluating Opdivo plus Yervoy in patients with previously untreated advanced or metastatic renal cell carcinoma (RCC) met its co-primary endpoint. This demonstrates superior overall survival (OS) compared to sunitinib in intermediate- and poor-risk patients.

$PFE {{ '2017-08-29T14:05:59+0000' | timeago}} • Announcement

$PFE and $BMY presented investigational Eliquis data for patients with non-valvular atrial fibrillation undergoing cardioversion. The outcomes measured in EMANATE, a Phase 4 clinical trial, were the occurrence of acute stroke, systemic embolism, major bleeding, clinically relevant non-major bleeding and all-cause death.

Recent Transcripts

MDT (Medtronic plc)
Tuesday, November 21 2017 - 1:00pm
ENDP (Endo International plc)
Thursday, November 9 2017 - 9:30pm
FVE (Five Star Quality Care Inc.)
Thursday, November 9 2017 - 3:00pm
GMED (Globus Medical, Inc.)
Wednesday, November 8 2017 - 10:30pm
GLYC (GlycoMimetics, Inc.)
Wednesday, November 8 2017 - 1:30pm
REGN (Regeneron Pharmaceuticals, Inc.)
Wednesday, November 8 2017 - 1:30pm
TARO (Taro Pharmaceutical Industries Ltd.)
Wednesday, November 8 2017 - 1:00pm
RIGL (Rigel Pharmaceuticals, Inc.)
Tuesday, November 7 2017 - 10:00pm
MNK (Mallinckrodt Public Limited Company)
Tuesday, November 7 2017 - 1:30pm
EBS (Emergent BioSolutions, Inc.)
Thursday, November 2 2017 - 9:00pm
FMS (Fresenius Medical Care AG & Co. KGAA)
Thursday, November 2 2017 - 8:30pm
NVO (Novo Nordisk A/S)
Thursday, November 2 2017 - 1:16pm
NUS (Nu Skin Enterprises Inc.)
Wednesday, November 1 2017 - 9:00pm
GERN (Geron Corporation)
Wednesday, November 1 2017 - 8:30pm
EVHC (Envision Healthcare Holdings, Inc.)
Wednesday, November 1 2017 - 12:30pm
NVO (Novo Nordisk A/S)
Wednesday, November 1 2017 - 11:31am
ARRY (Array BioPharma Inc.)
Tuesday, October 31 2017 - 1:00pm
MRK (Merck & Co. Inc.)
Friday, October 27 2017 - 12:00pm
SGEN (Seattle Genetics, Inc.)
Thursday, October 26 2017 - 8:30pm
BMY (Bristol-Myers Squibb Company)
Thursday, October 26 2017 - 2:30pm

AlphaGraphics you may like